NCT07321067Not yet recruiting
Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
the Objectives of this study are: • Primary Objective: To prospectively evaluate overall survival (OS), ICI-specific survival (OS-ICI), and progression-free survival (PFS) in patients with advanced HCC treated with immune checkpoint inhibitors. the main question it aims to answer is: What are the clinical outcomes (overall survival, progression-free survival, and OS-ICIs) of immune checkpoint inhibitor therapy in patients with advanced hepatocellular carcinoma? Participants already taking immune checkpoint inhibitors as part of their regular medical care.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 75 (estimated)
- First submitted
- 21 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Ahmed Karam Helmy
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07321067
What you commit to
- Study type: Observational
- Planned participants: 75
- From 1 Jan 2026 to the primary completion date, 1 Nov 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior liver transplantation.
- patients with concurrent malignancies other than HCC.
Other illness
- Active autoimmune disease requiring systemic immunosuppression.
Other
- Child-Pugh C liver function.
Who the study is looking for
- Adults (≥18 years) with radiologically or histologically confirmed advanced HCC
- Candidates for systemic immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab).
- Patients with preserved liver function. ( up to G2 using ALBI score or up to B (7 ) using Child-Pugh socring system) .
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| sSohag oncology centre Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
| Sohag university hospitals Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.